0.25Open0.48Pre Close92 Volume101 Open Interest327.50Strike Price6.35KTurnover27.02%IV1.82%PremiumOct 11, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.79Extrinsic Value100Contract SizeAmericanOptions Type0.2155Delta0.0469Gamma424.22Leverage Ratio-0.5070Theta0.0035Rho91.41Eff Leverage0.0676Vega
Amgen Stock Discussion
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks people wish they loaded up on, but I highly Suggest you buy some now. This isn't a Pump article. Read the facts & decide for yourself. People mostly miss out the the explosive growth curve and ...
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ fell 19 basis points, the $Dow Jones Industrial Average (.DJI.US)$ fell 70, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 4 basis points.
MACRO
Wednesday, Crude Oil Inventories were cut by 4.4M bar...
My name is Kevin Travers; here stonks and stories mooving the U.S. stock market today.
$Amgen (AMGN.US)$ fell 4%, the lowest on the Nasdaq 100 after the firm posted results from two phase th...
Will go below 300, can wait
Gapping up
$Shopify (SHOP.US)$ stock soared 17% after the e-commerce platform surpassed quarterly revenue expectations, with its artificial intelligence-powered tools attracting more merchants.
$Disney (DIS.US)$ stock rose by 0.16% in volatile trading as its Entertainment unit, housing Disney+, Hulu, and ESPN+, turning a profit for the first time.
Gapping down
$Super Micro Computer (SMCI.US)$ stock fell 14.2% follo...
Amgen (AMGN) reported adjusted EPS of $3.96 in Q1 on revenue of $7.45B that grew 22% Y/Y. The drugmaker had also tweaked its annual outlook at the time, guiding for adjusted EPS of $19 to $20.20 on revenue of $32.5B to $33.8B.
With the expectation of continued positive commentary on MariTide, the company’s injected GLP-1 weight-lo...
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Eli Lilly and Co (LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron (GERN.US)$ : Imetelstat
$Merck & Co (MRK.US)$ : V116
$Amgen (AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Merck & Co (MRK.US)$ : KEYTRUDA ...
No comment yet